Overview

A 106-gene solid-tumor NGS panel is a broad genomic product intended to surface medication-guiding alterations across many cancer types from a single test. For distributors and hospital labs, sourcing such a panel is a strategic decision: the right partner reduces repeat testing and strengthens the credibility of every report issued. This article lays out a practical sourcing checklist centered on the features that matter most.

Sourcing Criteria for a 106-Gene Panel

Begin with content fit. The panel should cover the drivers, resistance markers, and biomarker signatures (such as tumor mutational burden or homologous-recombination status) that your prescribers actually use, and the menu should be stated explicitly rather than implied. Request the analytical validation package: limit of detection for low allele fractions, specificity, and how copy-number and fusion calls are confirmed.

Accreditation is non-negotiable. Confirm CAP/CLIA-style oversight or an applicable CE mark, and verify that the laboratory can ship and report in your target markets without compliance gaps. Turnaround and sample flexibility — accepted tissue types, minimum input, and cold-chain needs — should match your logistics reality, not just the brochure.

Validation and Support

A distributor-grade panel lives or dies on its reporting layer. Look for structured, clinician-ready outputs that rank alterations by actionability and cite the evidence behind each recommendation, plus access to interpretation support when a variant is ambiguous. Pricing should be transparent, with volume tiers and no hidden re-extraction or re-run fees. Ask whether the vendor offers integration support for your LIS or EMR, since smooth data flow reduces manual errors and speeds report delivery to clinicians.

Finally, ask about update cadence. Genomic knowledge changes quickly, so the annotation engine behind the panel should be refreshed regularly; a static database quietly erodes clinical value over time.

FAQ

Q: What makes a 106-gene panel suitable for medication guidance?
A: Breadth plus validated calling of drivers, resistance markers, and biomarkers such as TMB or HRD that inform therapy choice.

Q: Which accreditations should a buyer verify?
A: CAP/CLIA-style laboratory oversight or a relevant CE mark, depending on the intended market.

Q: How often should the annotation database update?
A: Regularly — at least several times a year — so newly actionable variants reach reports promptly.

Q: Can one panel serve many tumor types?
A: Yes, a solid-tumor panel is designed for cross-cancer use, which is why it suits distributors serving diverse oncology practices.